Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K961673
    Date Cleared
    1996-07-15

    (75 days)

    Product Code
    Regulation Number
    864.8625
    Reference & Predicate Devices
    Predicate For
    N/A
    Why did this record match?
    Reference Devices :

    K943336

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    R&D Retic-PG™ is a tri-level, assayed hematology control designed to document and monitor reticulocyte values obtained from the CELL-DYN® 3500 System.

    Device Description

    R&D Retic-PG is an in vitro diagnostic reagent composed of human erythrocytes and a reticulocyte surrogate suspended in a plasma-like fluid with preservatives. It is composed of stable materials that provide a means of verifying accuracy and precision of CELL-DYN® 3500 reticulocyte results. R&D Retic-PG is available in three levels of reticulocytes and is stained and run in the same manner as patient specimens.

    AI/ML Overview

    Here's an analysis based on the provided text, outlining the acceptance criteria and study information for the R&D Retic-PG™ HEMATOLOGY CONTROL device:

    1. Table of Acceptance Criteria and Reported Device Performance

    Acceptance CriterionReported Device Performance
    StabilityMet acceptance criteria for recovery of values within the Expected Range through the life of the product.
    Shelf LifeEstablished as 62 days from shipment if stored at 2 -8°C.
    Open-Vial StabilityEstablished as 20 days.
    Substantial EquivalenceDemonstrated to be substantially equivalent to R&D Retic-I™.

    Note: The document states that the stability studies "met acceptance criteria," but it does not explicitly define what those criteria were (e.g., a specific percentage of recovery, a defined range limit).

    2. Sample size used for the test set and the data provenance

    The document does not specify the sample size used for the test set or the data provenance (e.g., country of origin, retrospective or prospective nature) for the performance data. It only states "Results of studies met acceptance criteria."

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

    This information is not provided in the document. The device is a hematology control, and the "ground truth" would likely refer to the established expected range of reticulocyte values, which would be determined through laboratory methods rather than expert consensus on individual cases.

    4. Adjudication method for the test set

    This information is not applicable and therefore not provided. The study focuses on the stability and performance of a control solution against an expected range, not on human interpretation or adjudication of diagnostic findings.

    5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    An MRMC comparative effectiveness study was not done. This device is a hematology control, not an AI diagnostic tool, so such a study would not be relevant.

    6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done

    This concept is not applicable to this device. The R&D Retic-PG™ is a control reagent used to verify the accuracy and precision of a hematology analyzer (CELL-DYN® 3500), not a standalone algorithm. Its performance is evaluated against an expected range by observing the output of the instrument.

    7. The type of ground truth used

    The ground truth used for evaluating the R&D Retic-PG™ would be the expected range of reticulocyte values for the control materials. This range is likely established through a rigorous internal characterization process using reference methods and statistical analysis.

    8. The sample size for the training set

    This information is not provided and is likely not applicable in the traditional sense of machine learning. As a control reagent, its "training" involves establishing its stable characteristics and expected ranges through manufacturing and quality control processes.

    9. How the ground truth for the training set was established

    This information is not explicitly detailed in the provided document. However, based on the nature of a hematology control, the "ground truth" (i.e., the expected range of values) for the manufacturing and characterization (analogous to training) would be established through:

    • Extensive testing: Running numerous replicates of the control material on the target instrument (CELL-DYN® 3500) and possibly reference methods.
    • Statistical analysis: Determining the mean and standard deviation of results to establish an acceptable range.
    • Comparison to predicate device: The document mentions substantial equivalence to R&D Retic-I™, implying that its performance characteristics would be informed by established ranges for similar predicate controls.
    • Quality control procedures: Adherence to established manufacturing and quality assurance protocols for in vitro diagnostics.
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1